Pharma

The two-day conference and one-day exhibition provides the perfect venue for easy, informal discussions for manufacturing, packaging, laboratory services and more!

The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on, but access to funding and large patient cohorts, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress. The 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need.

The CNS Summit has become the premiere event for all those involved in clinical development to meet, network, and participate in initiatives that will shape the future. The summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. The mission is to have a positive impact on the success of clinical development programs. Join the pharma and biotech R&D leaders, the top tech companies involved in clinical development and healthcare innovation, investigator sites, service companies, and the regulators from FDA and EMA.

“The Macrophage-directed Therapies Summit is returning for the 4th year, back to Boston – and continues to be the leading industry-focused forum uniting this emerging community of over 100 leaders to review cutting-edge advances in the discovery, preclinical, translational, and clinical development of macrophage-directed therapies.Covering discovery to the clinic and a brand-new Biomarkers Bootcamp, the summit is returning with two tracks of content.Join the likes of Gilead Sciences, Pionyr Immunotherapeutics, KAHR Medical, Codiak BioSciences, Ichnos Sciences, and Enlivex Therapeutics Ltd, and receive the latest updates on clinical progress, novel approaches, and targets to broaden the spectrum of macrophage targeting. With continuing growth in the macrophage space, delve into:
CD47 targeting and other ‘don’t eat me’ signals
Safety concerns due to model translatability and dosing
Optimal combination or monotherapy discovery
Learn from our expert speaker faculty, who will be sharing more exclusive new or unpublished insights than ever before.”

Connect with top-notch industry speakers delivering impactful presentations with practical solutions and best practices to take you to the next level in leading and managing the business aspects of clinical trials. It’s a place where clinical research professionals can connect on the latest topics, trends and technologies for streamlining the business aspects of clinical trials. Areas covered are clinical trial outsourcing and vendor management, contracting and budgeting, financial management, business operations and accelerating clinical study start-up.

Capture the unmatched potential of these versatile stem cells in regenerative medicine and cell therapy by advancing scale-up, differentiation and quality to reduce variability and ensure stable and robust cell lines. Gain valuable insights from industry experts, through exclusive talks and discussions, into approaches to transform your manufacturing processes by exploring technology innovations, leveraging automation and AI, evolving analytics and advancing cryopreservation.

Connect with iPSC trailblazers, including Century Therapeutics, Sana Biotechnology and Novo Nordisk, to create best-in-class iPSC-derived cell therapies for immuno-oncology and regenerative medicine.

The Innate Killer Summit returns for its 7th year as the industry-defining forum advancing the field to achieve clinical success. Spanning the current drug development landscape, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies.Join over 200 experts to characterize and contrast cell sources, supercharge combinations, optimize CMC workflows, examine expansion protocols for high-quality products at scale, and move the field towards persistent, scalable, and cost-effective innate immune cell therapies. Promising unpublished data, interactive discussion, and engaging networking opportunities join the 7th Innate Killer Summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.

The momentum of innate immune cell R&D is growing exponentially to harness innate immune responses in oncology, realise scaled allogeneic manufacturing, and drive commercial stage-products. Now is the time to gather this burgeoning community at the crucible of innovation: in Europe.The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T, NK, and Macrophage developers in October to chase the holy grail of efficacious, off-the-shelf, solid tumour immunotherapies through innate cell targeting and engineering.The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T, NK, and Macrophage developers in October to chase the holy grail of efficacious, off-the-shelf, solid tumour immunotherapies through innate cell targeting and engineering.